Epithalon — the telomerase-activation peptide, explained
Epithalon (also spelled Epitalon, Epithalamin; INN: epitalon) is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly. It was developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology in the 1990s as a synthetic analog of epithalamin, a pineal-gland extract. Epithalon is the most-studied compound from the Khavinson research program on short regulatory peptides, with a body of literature focused on telomerase activation, circadian gene expression, and age-related physiological markers. It sits in a research category largely parallel to the mainstream Western peptide literature, which is both a feature and a limitation of the evidence base. This primer covers the molecule, the Khavinson research program, what's been studied, the honest limits of the data, and what researchers should know.
The molecule. Epithalon is a tetrapeptide: Ala-Glu-Asp-Gly. Molecular weight is 390.4 Da (free acid form). It is one of the smallest peptides in regular research use — by way of comparison, GHK (in GHK-Cu) is three residues, epithalon is four. The small size has practical implications: epithalon is unusually stable compared to larger peptides, tolerates a wider temperature range, and has shown activity via oral administration in some rodent studies (though injectable routes are the dominant research approach).
The Khavinson research program. Vladimir Khavinson's group has published several hundred papers on short regulatory peptides including epithalon, thymalin, cortexin, and a family of 2-4 residue peptides with proposed tissue-specific regulatory effects. Most of this literature is Russian-language or Russian-first-authored, published in journals with relatively limited Western readership (Bull Exp Biol Med, Neuro Endocrinol Lett, Advances in Gerontology). The program predates modern large-scale reproducibility norms, and independent replication from non-Khavinson groups is thinner than the absolute citation count suggests. This does not invalidate the research — but serious readers should weight it with awareness of the provenance.
Published literature — primary sources. The most-cited Western-indexed paper is Khavinson VK, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003;135(6):590-592 (doi: 10.1023/a:1025493705728). This paper documents the telomerase-activation observation in human fetal lung fibroblast cultures — the foundational experimental result that anchors most subsequent epithalon research. For the broader program context, Anisimov VN, Khavinson VKh. Peptide bioregulation of aging: results and prospects. Biogerontology. 2010;11(2):139-149 is a useful overview of the Khavinson program's ambitions and evidence.
Proposed mechanisms. The two most-cited mechanistic hypotheses are (1) telomerase activation — epithalon administration has been reported to increase telomerase activity and extend telomere length in cell culture, with downstream implications for cellular senescence, and (2) circadian gene regulation — rodent studies from the Khavinson program show epithalon modulates pineal melatonin secretion and restores age-related attenuation of circadian gene expression. A third, more speculative proposal involves direct DNA binding and transcription factor–like activity of the tetrapeptide itself, which has been advanced in some Khavinson papers but remains less established than the telomerase and circadian claims.
What's been studied — honestly. The rodent and in vitro evidence is broad: telomerase activity in human fibroblast cultures (Khavinson 2003 and subsequent), pineal function and melatonin rhythms in aged rats, tumor incidence in long-lived mouse strains, immune function in aged mice, and general mortality endpoints in small rodent longevity studies. Human data is limited: a small number of open-label studies in elderly populations on general health markers, typically with sample sizes under 100 participants and without blinding or placebo controls. No large randomized controlled trial has established epithalon's effect on a hard clinical endpoint (lifespan, disease incidence, validated biomarker) in a human population to the standard of modern pharmaceutical evidence.
Where the evidence is weaker than commonly cited. Telomerase activation itself, while reproducible in the cited human fibroblast cultures, is not necessarily beneficial — telomerase upregulation is also a hallmark of oncogenesis. The Khavinson program's position is that epithalon activates telomerase in a controlled, physiological manner that does not produce the unconstrained activation seen in cancer cells. This distinction is plausible but not definitively demonstrated at the mechanistic level in the published literature. Research-context users interested in telomerase pharmacology should be aware of this open question.
Administration routes and dose ranges. Rodent studies have used intraperitoneal, subcutaneous, intranasal, and oral routes. Published rodent doses are typically 0.1-1 mg/kg administered in cycles (e.g., daily for 10 days, then 20 days off, repeated). Human pilot studies have used subcutaneous or intramuscular injection at 5-10 mg per administration, typically in short cycles of 10-20 doses. The cycling protocol is a distinctive feature of the Khavinson program's protocols and is not typical of other peptide research.
Storage, stability, and handling. Lyophilized epithalon is stable at 2–8 °C for years when properly dried — unusually stable by peptide standards given its small size. Reconstituted solutions should be refrigerated and used within 30 days. The pen format stability window depends on the solvent system. Do not freeze the pen. Protect from light. Room temperature exposure is more tolerated than for the GLP-1-class peptides, but still best minimized.
What the COA should say. A batch-specific COA for epithalon should include (1) identity confirmation by HPLC-MS against the theoretical mass of 390.4 Da — at this small size, mass identification is straightforward and tolerance should be tight (± 0.1 Da), (2) purity by reverse-phase HPLC-UV, (3) residual solvent profile per ICH Q3C, (4) endotoxin by LAL in EU/mg. Sequence verification by amino acid analysis is useful for a tetrapeptide to confirm ordering — several positional scramble isomers have identical mass but different sequence.
Research-use only. Vivaprime supplies epithalon as research reference material for qualified researchers engaged in in-vitro laboratory work. Epithalon has not been approved by the FDA or by any Western regulatory agency for any therapeutic indication. In Russia it has been registered as a drug for some age-related indications, but this registration does not translate to Western regulatory approval. Nothing on this page constitutes a therapeutic, diagnostic, or consumption recommendation. Serious readers should treat the Khavinson-program evidence base with appropriate awareness of its provenance. Purchasers affirm the research-use agreement at checkout.